Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vaxcyte, Inc.
Report date December 30, 2022 · Filed January 04, 2023
Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.95 · Expires 2032-12-30 | Direct | 15,000 |
Reported balance
After 2022-12-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-30 · Grant · Acquired 15,000 · Balance 15,000 F2: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| Common StockSEC Table I · non-derivative | Direct | 17,827 |
Reported balance
Holding disclosure · report date 2022-12-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 17,827 F1: Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy Fairman Family Trust | 286,227 |
Reported balance
Holding disclosure · report date 2022-12-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 286,227 |
| Common StockSEC Table I · non-derivative | IndirectBy AF 2020 Irrevocable Trust | 50,000 |
Reported balance
Holding disclosure · report date 2022-12-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 50,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022.
F2: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2022 Filed Jan 4, 2023 16:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000968 · doc4.xml · derivative · entry 4 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-12-30 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 18:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001209191-22-054858 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 286,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 16:57 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $25.50 | $127,500.00 |
DisclosureSEC source: 0001209191-22-053579 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 296,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 16:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 336 | $27.14 | $9,118.44 |
DisclosureSEC source: 0001209191-22-049025 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 301,227 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.09 to $27.23. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 16:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,664 | $26.54 | $123,773.70 |
DisclosureSEC source: 0001209191-22-049025 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 301,563 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.04 to $27.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 519 | $26.38 | $13,691.22 |
DisclosureSEC source: 0001209191-22-049025 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,143 F1 · kind: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 19:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $25.70 | $128,507.50 |
DisclosureSEC source: 0001209191-22-044659 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 306,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.50 to $26.035. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 19:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $25.50 | $255,000.00 |
DisclosureSEC source: 0001209191-22-044659 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 311,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 20, 2022 Filed May 24, 2022 16:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,112 | $25.50 | $104,856.00 |
DisclosureSEC source: 0001209191-22-031619 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 321,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 05, 2022 Filed May 9, 2022 16:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 888 | $25.80 | $22,914.40 |
DisclosureSEC source: 0001209191-22-027848 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 325,339 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.58 to $26.19. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 17:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $25.59 | $127,950.00 |
DisclosureSEC source: 0001209191-22-023695 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 326,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $25.50 | $255,000.00 |
DisclosureSEC source: 0001209191-22-019027 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Indirect · By Fairman Family Trust Disclosed balance after: 331,227 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-22-016524 · doc4.xml · derivative · entry 4 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 20:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016524 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,629 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-071376 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,345 Underlying: Common Stock · 4,750 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 175 | $24.08 | $4,214.00 |
DisclosureSEC source: 0001209191-21-071376 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,160 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.285. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,575 | $23.58 | $107,878.50 |
DisclosureSEC source: 0001209191-21-071376 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,335 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.02 to $24.005. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $1.79 | $8,502.50 |
DisclosureSEC source: 0001209191-21-071376 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2021 Filed Feb 8, 2022 17:27 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,469 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-22-007789 · doc4.xml · derivative · entry 4 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,626 Underlying: Common Stock · 4,469 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 20, 2021 Filed Feb 8, 2022 17:27 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,469 | $1.79 | $7,999.51 |
DisclosureSEC source: 0001209191-22-007789 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,619 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-070572 · doc4.xml · derivative · entry 5 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,095 Underlying: Common Stock · 4,619 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,619 | $22.50 | $103,927.50 |
DisclosureSEC source: 0001209191-21-070572 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,160 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,619 | $1.79 | $8,268.01 |
DisclosureSEC source: 0001209191-21-070572 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 17:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 131 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-069292 · doc4.xml · derivative · entry 5 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,714 Underlying: Common Stock · 131 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 17:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 131 | $22.50 | $2,947.50 |
DisclosureSEC source: 0001209191-21-069292 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,160 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 17:20 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 131 | $1.79 | $234.49 |
DisclosureSEC source: 0001209191-21-069292 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,016 shares acquired under the Employee Stock Purchase Plan on November 17, 2021. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 18:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-061940 · doc4.xml · derivative · entry 5 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,845 Underlying: Common Stock · 4,750 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 18:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,750 | $22.69 | $107,777.50 |
DisclosureSEC source: 0001209191-21-061940 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,144 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.54 to $22.855. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 18:00 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $1.79 | $8,502.50 |
DisclosureSEC source: 0001209191-21-061940 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 19:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-058125 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,595 Underlying: Common Stock · 4,750 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 19:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 139 | $26.47 | $3,679.33 |
DisclosureSEC source: 0001209191-21-058125 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,144 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 19:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,611 | $26.16 | $120,623.76 |
DisclosureSEC source: 0001209191-21-058125 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,283 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.415 to $26.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 19:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $1.79 | $8,502.50 |
DisclosureSEC source: 0001209191-21-058125 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 18:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-053901 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,345 Underlying: Common Stock · 4,750 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 18:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,218 | $25.70 | $82,702.60 |
DisclosureSEC source: 0001209191-21-053901 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,144 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.06 to $26.015. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 18:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,532 | $24.70 | $37,840.40 |
DisclosureSEC source: 0001209191-21-053901 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,362 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.06 to $25.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 18:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $1.79 | $8,502.50 |
DisclosureSEC source: 0001209191-21-053901 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-048429 · doc4.xml · derivative · entry 5 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,095 Underlying: Common Stock · 4,750 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,750 | $22.70 | $107,825.00 |
DisclosureSEC source: 0001209191-21-048429 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,144 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.50 to $22.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $1.79 | $8,502.50 |
DisclosureSEC source: 0001209191-21-048429 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-044018 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,845 Underlying: Common Stock · 4,750 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 136 | $24.80 | $3,372.80 |
DisclosureSEC source: 0001209191-21-044018 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,144 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.79 to $24.81. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,614 | $24.36 | $112,397.04 |
DisclosureSEC source: 0001209191-21-044018 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,280 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.77 to $24.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:41 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $1.79 | $8,502.50 |
DisclosureSEC source: 0001209191-21-044018 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 16:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,241 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-039204 · doc4.xml · derivative · entry 7 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,595 Underlying: Common Stock · 2,241 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48th of the shares vest monthly thereafter. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 16:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 7,259 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-039204 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,259 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 16:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,500 | $22.50 | $213,750.00 |
DisclosureSEC source: 0001209191-21-039204 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,144 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 16:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,241 | $1.79 | $4,011.39 |
DisclosureSEC source: 0001209191-21-039204 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 16:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 7,259 | $0.04 | $290.36 |
DisclosureSEC source: 0001209191-21-039204 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 943 shares acquired under the Employee Stock Purchase Plan on May 17, 2021. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 19:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,793 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-028190 · doc4.xml · derivative · entry 4 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,836 Underlying: Common Stock · 2,793 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48th of the shares vest monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.